|
| |
EPIX PharmaceuticalsEPIX Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients. The company has five internally-discovered therapeutic and imaging drug candidates currently in clinical trials targeting conditions such as depression, Alzheimer's disease, cardiovascular disease and obesity. These drug candidates include PRX-08066 in Phase 2 clinical development for pulmonary hypertension associated with chronic obstructive pulmonary disease, PRX-03140 which is in a Phase 2a clinical trial in Alzheimer's disease, PRX-00023 which is in Phase 2b clinical development to treat major depression, and PRX-07034, which recently completed a Phase 1b trial and is in clinical development for the treatment of obesity and cognitive impairment. The company also has a blood-pool imaging agent (Vasovist™) approved in 32 countries and marketed in Europe. EPIX has collaborations with leading organizations, including GlaxoSmithKline, Amgen, Cystic Fibrosis Foundation Therapeutics, and Bayer Schering Pharma AG, Germany.
| Contact Details: |
| 4 Maguire Road |
| Lexington |
| Massachusetts |
| 02421 |
| United States of America |
| Tel: | 781-761-7600 |
| Fax: | 781-761-7641 |
| Email: | info@epixpharma.com |
| WWW: | www.epixmed.com/
|
|
Loading...
|
Recent Publications by EPIX Pharmaceuticals: |  |
Bioactive Conformational Biasing: A New Method for Focusing Conformational Ensembles on Bioactive-Like Conformers.
Computational approaches that rely on ligand-based information for lead... | 15th October, 2009
| Epix Pharmaceuticals Ltd., 3 Hayetzira St., Ramat Gan 52521, Israel.
| J Chem Inf Model. 2009 Oct 14.
DOI Direct Link |
SeleX-CS: a new consensus scoring algorithm for hit discovery and lead optimization.
Identifying active compounds (hits) that bind to biological targets of... | 30th May, 2009
| Epix Pharmaceuticals Ltd., 3 Hayetzira Street, Ramat Gan 52521, Israel.
| J Chem Inf Model. 2009 Mar;49(3):623-33.
DOI Direct Link |
EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus.
Thrombus (blood clot) is implicated in a number of life threatening... | 24th June, 2008
| EPIX Pharmaceuticals, 4 Maguire Road, Lexington, Massachusetts 02421, USA.
| J Am Chem Soc. 2008 May 7;130(18):6025-39. Epub 2008 Apr 8.
DOI Direct Link |
Collagen-targeted MRI contrast agent for molecular imaging of fibrosis.
Thrombus (blood clot) is implicated in a number of life threatening... | 17th January, 2008
| EPIX Pharmaceuticals, Inc. 4 Maguire Road, Lexington, MA 02421, USA.
| Angew Chem Int Ed Engl. 2007;46(43):8171-3.
DOI Direct Link |
Albumin binding, relaxivity, and water exchange kinetics of the diastereoisomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent.
The amphiphilic gadolinium complex MS-325... | 20th October, 2007
| EPIX Pharmaceuticals, Cambridge, MA 02142, USA.
| Inorg Chem. 2007 Aug 6;46(16):6632-9. Epub 2007 Jul 11.
DOI Direct Link |
→View more EPIX Pharmaceuticals research publications. |
Press Releases on EPIX Pharmaceuticals:
|
 |
| Reportlinker Adds Imaging Agents - A Worldwide Market Review |
20th November, 2009 |
Reportlinker |
NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
Imaging Agents - A Worldwide Market Review
http://www.reportlinker.com
|
| Reportlinker Adds Ion Channel Modulator Pipelines: Targets and Agents in Development |
26th October, 2009 |
Reportlinker |
-- Prospects for ion channel modulators and commercial successes to date--
Pipeline activities, expert views, and survey results
Ion Channel Modulator Pipelines: Targets and Agents in
|
| Joseph F. Finn, Jr., Assignee for the Benefit of Creditors of EPIX Pharmaceuticals, Inc., Releases Statement Regarding Liquidation Process |
22nd October, 2009 |
Joseph F. Finn, Jr., C.P.A. |
WELLESLEY HILLS, Mass., Oct. 22 /PRNewswire/ -- The previously announced auction of assets of EPIX Pharmaceuticals, Inc. was conducted on October 21, 2009. As of today, claims filed against the
|
| EPIX Pharmaceuticals Announces FDA Approval of a Physician-Sponsored IND for Fourth 6-month Open Label Extension of PRX-03140 for Alzheimer's Disease Patient |
16th October, 2009 |
Joseph F. Finn, Jr., C.P.A. |
WELLESLEY Hills, Mass., Oct. 16 /PRNewswire/ -- The FDA has approved a Physician-Sponsored IND and continuation of the fourth 6-month open label extension of PRX-03140, a novel 5HT4 partial agonist
|
| Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team |
16th April, 2009 |
Proteolix, Inc. |
SOUTH SAN FRANCISCO, Calif., April 16 /PRNewswire/ -- Proteolix, Inc. today announced the appointment of Craig C. Parker to the post of Senior Vice President, Finance and Corporate Development and
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 432 times since April 2007, the link to the organisation's website has been followed 65 times Recent Search Terms used to find this page: epix pharmaceuticals | Mike Webb and Epix | mike webb epix | Epix Pharmaceutical | . Search for more companies in Lexington Search for more companies in Massachusetts This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for EPIX Pharmaceuticals |
